AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Cancer Cell

Volumn 11, Issue 1, 2007, Pages 83-95

  Batchelor, Tracy T ^a   Sorensen, A Gregory ^a   di Tomaso, Emmanuelle ^a   Zhang, Wei Ting ^a   Duda, Dan G ^a   Cohen, Kenneth S ^a   Kozak, Kevin R ^a   Cahill, Daniel P ^a   Chen, Poe Jou ^a,b   Zhu, Mingwang ^a   Ancukiewicz, Marek ^a   Mrugala, Maciej M ^a   Plotkin, Scott ^a   Drappatz, Jan ^a   Louis, David N ^a   Ivy, Percy ^c   Scadden, David T ^a   Benner, Thomas ^a   Loeffler, Jay S ^a   Wen, Patrick Y ^a   Jain, Rakesh K ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b Massachusetts Institute of Technology   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; BEVACIZUMAB; CORTICOSTEROID; FIBROBLAST GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN INHIBITOR;

ARTICLE; BRAIN EDEMA; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEM CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 33846149645     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.11.021     Document Type: Article

References (54)

1. Aghi M., Cohen K.S., Klein R.J., Scadden D.T., and Chiocca E.A. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 66 (2006) 9054-9064
2. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., Martinive P., Gregoire V., Feron O., and Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11 (2005) 743-750
3. Benner T., Wisco J.J., van der Kouwe A.J., Fischl B., Vangel M.G., Hochberg F.H., and Sorensen A.G. Comparison of manual and automatic section positioning of brain MR images. Radiology 239 (2006) 246-254
4. Bertolini F., Shaked Y., Mancuso P., and Kerbel R.S. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev. Cancer 6 (2006) 835-845
5. Boxerman J.L., Schmainda K.M., and Weisskoff R.M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am. J. Neuroradiol. 27 (2006) 859-867
6. Brown C.K., Khodarev N.N., Yu J., Moo-Young T., Labay E., Darga T.E., Posner M.C., Weichselbaum R.R., and Mauceri H.J. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett. 565 (2004) 167-170
7. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
8. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
9. Chamberlain M.C., Glantz M.J., Chalmers L., Van Horn A., Sloan A.E., and Lee H. Early necrosis following concurrent temozolomide and radiotherapy in adult patients with glioblastoma. J. Clin. Oncol. 24 Suppl (2006) 1513
10. Das A., Banik N.L., Patel S.J., and Ray S.K. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. Mol. Cancer 3 (2004) 36
11. Demidenko M. Mixed Effects Models. Theory and Application (2004), John Wiley & Sons, New York
12. Dennie J., Mandeville J.B., Boxerman J.L., Packard S.D., Rosen B.R., and Weisskoff R.M. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn. Reson. Med. 40 (1998) 793-799
13. Duda D.G., Cohen K.S., di Tomaso E., Au P., Klein R.J., Scadden D.T., Willett C.G., and Jain R.K. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J. Clin. Oncol. 24 (2006) 1449-1453
14. Duda D.G., Cohen K.S., Au P., Scadden D.T., Willett C.G., and Jain R.K. Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?. J. Clin. Oncol. (2007) in press
15. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
16. Fomchenko E.I., and Holland E.C. Origins of brain tumors-a disease of stem cells?. Nat. Clin. Pract. Neurol. 2 (2006) 288-289
17. Grossman S.A., and Batara J.F. Current management of glioblastoma multiforme. Semin. Oncol. 31 (2004) 635-644
18. Hollander M., and Wolfe D.A. Nonparametrical Statistical Inference (1973), John Wiley & Sons, New York
19. Ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., Hurwitz H.I., Kabbinavar F., Novotny W.F., Hillan K.J., and Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst. 97 (2005) 981-989
20. Jackson A., Jayson G.C., Li K.L., Zhu X.P., Checkley D.R., Tessier J.J., and Waterton J.C. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br. J. Radiol. 76 (2003) 153-162
21. Jain R.K., Safabakhsh N., Sckell A., Chen Y., Jiang P., Benjamin L., Yuan F., and Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA 95 (1998) 10820-10825
22. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
23. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
24. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3 (2006) 24-40
25. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., Kabbinavar F., Holden S.N., Novotny W.F., Frantz G.D., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24 (2006) 217-227
26. Kadambi A., Mouta Carreira C., Yun C.O., Padera T.P., Dolmans D.E., Carmeliet P., Fukumura D., and Jain R.K. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61 (2001) 2404-2408
27. Law M., Cha S., Knopp E.A., Johnson G., Arnett J., and Litt A.W. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 222 (2002) 715-721
28. Lichy M.P., Wietek B.M., Mugler III J.P., Horger W., Menzel M.I., Anastasiadis A., Siegmann K., Niemeyer T., Konigsrainer A., Kiefer B., et al. Magnetic resonance imaging of the body trunk using a single-slab, 3-dimensional, T2-weighted turbo-spin-echo sequence with high sampling efficiency (SPACE) for high spatial resolution imaging: initial clinical experiences. Invest. Radiol. 40 (2005) 754-760
29. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 16-24
30. Oh J., Cha S., Aiken A.H., Han E.T., Crane J.C., Stainsby J.A., Wright G.A., Dillon W.P., and Nelson S.J. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J. Magn. Reson. Imaging 21 (2005) 701-708
31. Ostergaard L., Sorensen A.G., Kwong K.K., Weisskoff R.M., Gyldensted C., and Rosen B.R. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn. Reson. Med. 36 (1996) 726-736
32. Pathak A.P., Schmainda K.M., Ward B.D., Linderman J.R., Rebro K.J., and Greene A.S. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn. Reson. Med. 46 (2001) 735-747
33. Pope W.B., Lai A., Nghiemphu P., Mischel P., and Cloughesy T.F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66 (2006) 1258-1260
34. Prados M.D., Lamborn K., Yung W.K., Jaeckle K., Robins H.I., Mehta M., Fine H.A., Wen P.Y., Cloughesy T., Chang S., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncol. 8 (2006) 189-193
35. Rafii S., Lyden D., Benezra R., Hattori K., and Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer 2 (2002) 826-835
36. Reardon D.A., Quinn J.A., Rich J.N., Desjardins A., Vredenburgh J., Gururangan S., Sathornsumetee S., Badruddoja M., McLendon R., Provenzale J., et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104 (2005) 1478-1486
37. Rempel S.A., Dudas S., Ge S., and Gutierrez J.A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. 6 (2000) 102-111
38. Schmainda K.M., Rand S.D., Joseph A.M., Lund R., Ward B.D., Pathak A.P., Ulmer J.L., Badruddoja M.A., and Krouwer H.G. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am. J. Neuroradiol. 25 (2004) 1524-1532
39. Segers J., Fazio V.D., Ansiaux R., Martinive P., Feron O., Wallemacq P., and Gallez B. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett. 244 (2006) 129-135 10.1016/j.canlet.2005.12.017 Published online January 17, 2006
40. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
41. Sorensen A.G., Patel S., Harmath C., Bridges S., Synnott J., Sievers A., Yoon Y.H., Lee E.J., Yang M.C., Lewis R.F., et al. Comparison of diameter and perimeter methods for tumor volume calculation. J. Clin. Oncol. 19 (2001) 551-557
42. Stoll B.R., Migliorini C., Kadambi A., Munn L.L., and Jain R.K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 102 (2003) 2555-2561
43. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., Larsson H.B., Lee T.Y., Mayr N.A., Parker G.J., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 10 (1999) 223-232
44. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
45. Tremont-Lukats I.W., and Gilbert M.R. Advances in molecular therapies in patients with brain tumors. Cancer Control 10 (2003) 125-137
46. van der Kouwe A.J., Benner T., Fischl B., Schmitt F., Salat D.H., Harder M., Sorensen A.G., and Dale A.M. On-line automatic slice positioning for brain MR imaging. Neuroimage 27 (2005) 222-230
47. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., Smith N.R., James N.H., Dukes M., Curwen J.O., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65 (2005) 4389-4400
48. Weis S.M., and Cheresh D.A. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437 (2005) 497-504
49. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 (2004) 145-147
50. Willett C.G., Boucher Y., Duda D.G., di Tomaso E., Munn L.L., Tong R.T., Kozin S.V., Petit L., Jain R.K., Chung D.C., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23 (2005) 8136-8139
51. Winkler F., Kozin S.V., Tong R., Chae S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
52. Wong E.T., Hess K.R., Gleason M.J., Jaeckle K.A., Kyritsis A.P., Prados M.D., Levin V.A., and Yung W.K. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17 (1999) 2572-2578
53. Yoshiji H., Harris S.R., and Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 57 (1997) 3924-3928
54. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93 (1996) 14765-14770